首頁 > 市場調查報告書 > 醫療設備

生技設備癌症

市場調查報告書

商品編碼

1560803

全球癌症腫瘤分析市場 - 2024 - 2031

Global Cancer Tumor Profiling Market - 2024 - 2031

出版日期: 2024年09月23日 | 出版商:

DataM Intelligence | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

報告概述

全球癌症腫瘤分析市場在 2023 年達到 95 億美元，預計到 2031 年將達到 191.5 億美元，在 2024-2031 年預測期間複合年成長率為 9.4%。

腫瘤分析是一項實驗室測試，用於檢查構成腫瘤生物學和癌症生長基礎的基因突變或其他變化。這些資訊可以幫助醫生根據腫瘤概況制定個人化的治療計劃。腫瘤分析是腫瘤科醫師用來確定患者腫瘤路徑是否與可用的標靶治療相符的技術。腫瘤分析可以深入分析導致癌症進展和治療抗藥性的腫瘤分子特徵。

腫瘤分析，也稱為生物標記測試，是對癌細胞進行詳細且靈敏的實驗室分析。該測試的目的是暴露特定的生物標記突變，並確定與任何發現的突變相符的標靶治療。腫瘤分析可以幫助指導和確定最有效的治療計劃。腫瘤分析從取得腫瘤組織樣本開始。通常透過核心活體組織切片收集組織。

市場動態：

司機

癌症盛行率增加

全球癌症腫瘤分析市場的需求是由多種因素所驅動的。癌症盛行率的上升推動了市場的成長。例如，根據 nih.gov 2023 年 1 月發表的一篇文章，預計美國將出現 1,958,310 例新癌症病例和 609,820 例癌症死亡。在經歷了二十年的下降之後，從 2014 年到 2019 年，前列腺癌的發生率每年增加 3%，意味著新增病例增加了 99,000 例。

此外，根據wcrf.org 的數據，包括非黑色素瘤皮膚癌(NMSC) 在內，2022 年全球癌症病例數為19,976,499 例。男性女性 9,175,141 人。此外，根據 IARC 的數據，2022 年將有近 2,000 萬新發癌症病例（包括非黑色素瘤皮膚癌 [NMSC]），同時有 970 萬人死於癌症（包括 NMSC）。據估計，大約五分之一的男性或女性一生中會罹患癌症，而大約九分之一的男性和十二分之一的女性會死於癌症。肺癌是 2022 年最常被診斷出的癌症，導致近 250 萬新病例，即全球八分之一的癌症之一（佔全球所有癌症的 12.4%）。

限制

與程序相關的高成本、缺乏醫療基礎設施、缺乏報銷政策以及樣本收集和儲存條件的技術問題等因素預計將阻礙市場。

細分市場分析

全球癌症腫瘤分析市場根據癌症類型、技術類型、生物標記類型、應用、最終用戶和地區進行細分。

下一代定序領域約佔全球癌症腫瘤分析市場佔有率的48.9%

預計下一代定序領域將在預測期內佔據最大的市場佔有率。在這個領域，技術進步將推動這個市場。

下一代定序（NGS），也稱為大規模並行定序，是捕捉大量癌症基因組資訊的有效方法。大多數 NGS 技術都圍繞著邊合成邊定序。每個待定序的 DNA 片段都與陣列結合，然後 DNA 聚合酶依序添加標記的核苷酸。高解析度相機捕獲來自每個整合的核苷酸的訊號，並記錄空間座標和時間。然後可以透過電腦程式推斷每個點的序列，以產生連續的 DNA 序列，稱為讀數。

例如，2023 年 4 月，安捷倫科技公司宣布推出 Agilent SureSelect Cancer CGP Assay，專為多種實體腫瘤類型的體細胞變異分析而設計。泛癌症檢測設計基於NGS面板，該面板包含全球領先的癌症資料庫中的679個基因，並與主要臨床癌症研究人員合作。

市場地理分析

北美約佔全球癌症腫瘤分析市場佔有率的 43.6%

預計北美地區將在預測期內佔據最大的市場佔有率。該地區癌症發病率的上升和技術進步有助於推動市場發展。

例如，根據 nih.gov 2024 年 1 月發表的一篇文章，預計美國將出現 2,001,140 例新癌症病例和 611,720 例癌症死亡。到 2021 年，癌症死亡率持續下降，由於吸菸的減少、某些癌症的早期發現以及輔助和轉移治療方案的改進，自 1991 年以來避免了超過 400 萬人死亡。然而，這些成果受到十大癌症中六種發病率上升的威脅。

此外，2023 年9 月，決策醫學領域的領導者Pillar Biosciences, Inc. 宣佈在全球推出oncoReveal Core LBx，這是一種僅供研究使用(RUO) 的下一代測序(NGS) 試劑盒，旨在使實驗室能夠基於液體活體組織切片的泛癌腫瘤分析解決方案。

Tumor profiling is a laboratory test to check for gene mutations or other alterations that make up the tumor biology and underlie the cancer growth. This information can help physicians build a personalized treatment plan based on the tumor profile. Tumor profiling is the technology oncologists use to determine if the pathways of a patient's tumor match up with available targeted treatments. Tumor profiling allows for deep analysis of a tumor's molecular characteristics that are responsible for cancer progression and therapy resistance.

Tumor profiling, also known as biomarker testing, is a detailed and sensitive laboratory analysis of cancer cells. The purpose of this testing expose specific biomarker mutations and identify targeted therapies matched to any found mutations. Tumor profiling can help guide and identify the most effective treatment plan. Tumor profiling starts with obtaining a sample of tumor tissue. The tissue is usually collected through a core biopsy.

Market Dynamics: Drivers

Increasing prevalence of cancer

The demand for the global cancer tumor profiling market is driven by multiple factors. The rising prevalence of cancers propels the market growth. For instance, according to an article published by nih.gov in January 2023, 1,958,310 new cancer cases and 609,820 cancer deaths are projected to occur in the United States. Cancer incidence increased for prostate cancer by 3% annually from 2014 through 2019 after two decades of decline, translating to an additional 99,000 new cases.

Moreover, according to wcrf.org, including non-melanoma skin cancer (NMSC) there were 19,976,499 cancer cases in 2022. When NMSC was excluded, this number dropped to 18,741,966 cancer cases around the world in 2022. Of these, 9,566,825 were in men and 9,175,141 in women. Moreover, according to IARC, There were close to 20 million new cases of cancer in the year 2022 (including nonmelanoma skin cancers [NMSCs]) alongside 9.7 million deaths from cancer (including NMSC). The estimates suggest that approximately one in five men or women develop cancer in a lifetime, whereas around one in nine men and one in 12 women die from it. Lung cancer was the most frequently diagnosed cancer in 2022, responsible for almost 2.5 million new cases, or one in eight cancers worldwide (12.4% of all cancers globally).

Restraints

Factors such as high cost associated with the procedure, lack of healthcare infrastructure, lack of reimbursement policies, and technical issues in sample collection and storage conditions are expected to hamper the market.

Market Segment Analysis

The global cancer tumor profiling market is segmented based on cancer type, technology type, biomarker type, application, end-user, and region.

The segment next-generation sequencing accounted for approximately 48.9% of the global cancer tumor profiling market share

The next-generation sequencing segment is expected to hold the largest market share over the forecast period. In this segment, technological advancements would drive this market.

Next-generation sequencing (NGS), also known as massively parallel sequencing, represents an effective way to capture a large amount of genomic information about a cancer. Most NGS technologies revolve around sequencing by synthesis. Each DNA fragment to be sequenced is bound to an array, and then DNA polymerase adds labeled nucleotides sequentially. A high-resolution camera captures the signal from each nucleotide becoming integrated and notes the spatial coordinates and time. The sequence at each spot can then be inferred by a computer program to generate a contiguous DNA sequence, referred to as a read.

For instance, in April 2023, Agilent Technologies Inc. announced the launch of the Agilent SureSelect Cancer CGP Assay designed for somatic variant profiling for a broad range of solid tumor types. The pan-cancer assay design is based on an NGS panel comprising 679 genes globally curated from leading cancer databases and in partnership with key clinical cancer researchers.

Market Geographical Analysis

North America accounted for approximately 43.6% of the global cancer tumor profiling market share

North America region is expected to hold the largest market share over the forecast period. The rising incidence of cancer, and technological advancements, in this region, help to propel the market.

For instance, according to an article published by nih.gov in January 2024, 2,001,140 new cancer cases and 611,720 cancer deaths are projected to occur in the United States. Cancer mortality continued to decline through 2021, averting over 4 million deaths since 1991 because of reductions in smoking, earlier detection for some cancers, and improved treatment options in both adjuvant and metastatic settings. However, these gains are threatened by increasing incidence for 6 of the top 10 cancers.

Moreover, in September 2023, Pillar Biosciences, Inc., the leader in Decision Medicine, announced the global launch of oncoReveal Core LBx, a research-use-only (RUO) next-generation sequencing (NGS) kit designed to enable laboratories with a solution for liquid biopsy-based pan-cancer tumor profiling.

Market Segmentation

By Cancer Type

Lung Cancer

Prostate Cancer

Breast Cancer

Colorectal Cancer

Melanoma cancer

Others

By Technology Type

Immunoassays

Next-Generation Sequencing

Polymerase Chain Reaction

In-Situ Hybridization

Microarray

Others

By Biomarker Type

Genomics Biomarker

Protein Biomarker

Others

By Application

Research Applications

Clinical Applications

Diagnostics

Personalized Medicines

Others

By End-User

Hospitals

Diagnostic Centers

Research and Academic Institutions

Others

By Region

North America

U.S.

Canada

Mexico

Europe

Germany

U.K.

France

Spain

Italy

Rest of Europe

South America

Brazil

Argentina

Rest of South America

Asia-Pacific

China

India

Japan

South Korea

Rest of Asia-Pacific

Middle East and Africa

Market Competitive Landscape

The major global players in the global cancer tumor profiling market include Qiagen N.V, NeoGenomics Laboratories, Genomic Health Inc., Caris Life Sciences, Helomics Corporation, NanoString Technologies Inc., Sysmex Corporation, Ribomed Biotechnologies Inc., Roche Diagnostics and Illumina Inc. among others.

Key Developments

In May 2024, Foundation Medicine Inc. announced the U.S. launch of FoundationOne(R)RNA, a tissue-based RNA sequencing test for the detection of cancer-related fusions across 318 genes. FoundationOne RNA enables reporting of fusions in all solid tumors and may be valuable for detecting fusions in certain cancers, such as non-small cell lung cancer (NSCLC), pancreatic cancer, cholangiocarcinoma, sarcoma, thyroid cancer, and bladder cancer.

In November 2023, Illumina Inc. announced a new generation of its distributed liquid biopsy assay for genomic profiling. The new TruSight(TM) Oncology 500 ctDNA v2 (TSO 500 ctDNA v2) is a research assay that enables noninvasive comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) from blood when tissue testing is not available or to complement tissue-based testing.

Why Purchase the Report?

To visualize the global cancer tumor profiling market segmentation based on cancer type, technology type, biomarker type, application, end-user, and region, as well as understand key commercial assets and players.

Identify commercial opportunities by analyzing trends and co-development

Excel data sheet with numerous data points of global cancer tumor profiling market level with all segments.

PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.

Product mapping is available in Excel consisting of key products of all the major players.

The global cancer tumor profiling market report would provide approximately 51 tables, 54 figures, and 181 Pages.

Target Audience 2024

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Cancer Type
3.2. Snippet by Technology Type
3.3. Snippet by Biomarker Type
3.4. Snippet by Application
3.5. Snippet by End-User
3.6. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Increasing Prevalence of Cancer
  - 4.1.1.2. Technological Advancements
  - 4.1.1.3. Government Initiatives and Fundings
- 4.1.2. Restraints
  - 4.1.2.1. High Costs of Procedure
  - 4.1.2.2. Lack of Healthcare Infrastructure
  - 4.1.2.3. Lack of Reimbursement Policies
  - 4.1.2.4. Technical Issues in Collecting Samples
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Unmet Needs
5.6. PESTEL Analysis
5.7. Patent Analysis
5.8. SWOT Analysis

6. By Cancer Type

6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 6.1.2. Market Attractiveness Index, By Cancer Type
6.2. Lung Cancer*
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Prostate Cancer
6.4. Breast Cancer
6.5. Colorectal Cancer
6.6. Melanoma Cancer
6.7. Others

7. By Technology Type

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
- 7.1.2. Market Attractiveness Index, By Technology Type
7.2. Immunoassays*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Next-Generation Sequencing
7.4. Polymerase Chain Reaction
7.5. In-Situ Hybridization
7.6. Microarray
7.7. Others

8. By Biomarker Type

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
- 8.1.2. Market Attractiveness Index, By Biomarker Type
8.2. Genomics Biomarker*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Protein Biomarker
8.4. Others

9. By Application

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.1.2. Market Attractiveness Index, By Application
9.2. Research Applications*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Clinical Applications
9.4. Diagnostics
9.5. Personalized Medicines
9.6. Others

10. By End-User

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.1.2. Market Attractiveness Index, By End-User
10.2. Hospitals*
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Diagnostic Centers
10.4. Research and Educational Institutions
10.5. Others

11. By Region

11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 11.1.2. Market Attractiveness Index, By Region
11.2. North America
- 11.2.1. Introduction
- 11.2.2. Key Region-Specific Dynamics
- 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
- 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
- 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.2.8.1. The U.S.
  - 11.2.8.2. Canada
  - 11.2.8.3. Mexico
11.3. Europe
- 11.3.1. Introduction
- 11.3.2. Key Region-Specific Dynamics
- 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
- 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
- 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.3.8.1. Germany
  - 11.3.8.2. UK
  - 11.3.8.3. France
  - 11.3.8.4. Italy
  - 11.3.8.5. Spain
  - 11.3.8.6. Rest of Europe
11.4. South America
- 11.4.1. Introduction
- 11.4.2. Key Region-Specific Dynamics
- 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
- 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
- 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.4.8.1. Brazil
  - 11.4.8.2. Argentina
  - 11.4.8.3. Rest of South America
11.5. Asia-Pacific
- 11.5.1. Introduction
- 11.5.2. Key Region-Specific Dynamics
- 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
- 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
- 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.5.8.1. China
  - 11.5.8.2. India
  - 11.5.8.3. Japan
  - 11.5.8.4. South Korea
  - 11.5.8.5. Rest of Asia-Pacific
11.6. Middle East and Africa
- 11.6.1. Introduction
- 11.6.2. Key Region-Specific Dynamics
- 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology Type
- 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
- 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12. Competitive Landscape

12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis

13. Company Profiles

13.1. Qiagen N.V *
- 13.1.1. Company Overview
- 13.1.2. Product Portfolio and Description
- 13.1.3. Financial Overview
- 13.1.4. Key Developments
13.2. NeoGenomics Laboratories
13.3. Genomic Health Inc.
13.4. Caris Life Sciences
13.5. Helomics Corporation
13.6. NanoString Technologies
13.7. Sysmex Corporation
13.8. Ribomed Biotechnologies Inc.
13.9. Roche Diagnostics
13.10. Illumina Inc. (*LIST NOT EXHAUSTIVE)